• Türkçe
    • English
  • English 
    • Türkçe
    • English
  • Login
View Item 
  •   DSpace@Medipol
  • Fakülteler
  • Tıp Fakültesi
  • Makale Koleksiyonu
  • View Item
  •   DSpace@Medipol
  • Fakülteler
  • Tıp Fakültesi
  • Makale Koleksiyonu
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation in children: Single-centre experience

Thumbnail

View/Open

Tam Metin / Full Text (320.1Kb)

Access

info:eu-repo/semantics/embargoedAccess

Date

2021

Author

Yaman, Yöntem
Elli, Murat
Şahin, Şifa
Özdilli, Kürşat
Bilgen, Hülya
Bayram, Nihan
Nepesov, Serdar
Anak, Sema

Metadata

Show full item record

Citation

Yaman, Y., Elli, M., Şahin, Ş., Özdilli, K., Bilgen, H., Bayram, N. ... Anak, S. (2021). Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation in children: Single-centre experience. Pediatric Transplantation, 25(5). https://dx.doi.org/10.1111/petr.13962

Abstract

Delayed recovery of thrombocytopenia is a well-known complication after allogeneic HSCT. Eltrombopag (ELT), a thrombopoietin receptor agonist (TRAs), induces platelet maturation and release. Mostly conducted in adults, some of the previous studies have shown that ELT seems to enhance platelet recovery for post-allogeneic HSCT thrombocytopenia, appears efficacious, and offers transfusion independence. To evaluate the safety and efficacy of ELT in pediatric patients with prolonged isolated thrombocytopenia (PIT) or secondary failure of platelet recovery (SFPR) after alloHSCT. Retrospective analysis of childhood patients who received treatment with ELT for persistent thrombocytopenia after alloHSCT between May 2016 and August 2019. We evaluated the safety and efficacy of ELT in 18 childhood patients with PIT or SFPR after alloHSCT. Eltrombopag (50 mg/d) treatment was started in all patients, above 6 years of age and 20 kg weight, who had thrombocytopenia despite neutrophil engraftment on the 30th day of HSCT. Our objective was to decrease the need for platelet transfusion and have a platelet count of more than 50 000/mu L. The overall response rate was 77.7%. The median time to achieve a platelet level above 30 000/mu L and 50 000/mu L was 21 and 44 days, respectively. In four patients, platelet count never reached 30 000/mm(3). In two patients, the treatment was discontinued due to grade 3 hepatotoxicity. Our study supports the efficacy and relative safety of ELT use for the treatment of PIT and SFPR seen after alloHSCT in children.

WoS Q Kategorisi

Q4

xmlui.dri2xhtml.METS-1.0.item-scopusquality

Q2

Source

Pediatric Transplantation

Volume

25

Issue

5

URI

https://dx.doi.org/10.1111/petr.13962
https://hdl.handle.net/20.500.12511/8428

Collections

  • Makale Koleksiyonu [3454]
  • PubMed İndeksli Yayınlar Koleksiyonu [3772]
  • Scopus İndeksli Yayınlar Koleksiyonu [5815]
  • WoS İndeksli Yayınlar Koleksiyonu [5982]



DSpace software copyright © 2002-2015  DuraSpace
Contact Us | Send Feedback
Theme by 
@mire NV
 

 




| Guide | Contact |

DSpace@Medipol

by OpenAIRE
Advanced Search

sherpa/romeo

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsInstitution AuthorORCIDTitlesSubjectsTypeLanguageDepartmentCategoryWoS Q ValueScopus Q ValuePublisherAccess TypeThis CollectionBy Issue DateAuthorsInstitution AuthorORCIDTitlesSubjectsTypeLanguageDepartmentCategoryWoS Q ValueScopus Q ValuePublisherAccess Type

My Account

LoginRegister

Statistics

View Google Analytics Statistics

DSpace software copyright © 2002-2015  DuraSpace
Contact Us | Send Feedback
Theme by 
@mire NV
 

 


|| Guide || Library || İstanbul Medipol University || OAI-PMH ||

Kütüphane ve Dokümantasyon Daire Başkanlığı, İstabul, Turkey
If you find any errors in content, please contact: [email protected]

Creative Commons License
DSpace@Medipol by İstanbul Medipol University Institutional Repository is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 Unported License..

DSpace@Medipol:


DSpace 6.2

tarafından İdeal DSpace hizmetleri çerçevesinde özelleştirilerek kurulmuştur.